Chen Chuanzhi, Chen Yi, Jin Xin, Ding Yongfeng, Jiang Junjie, Wang Haohao, Yang Yan, Lin Wu, Chen Xiangliu, Huang Yingying, Teng Lisong
Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
Front Mol Biosci. 2022 Apr 11;9:793403. doi: 10.3389/fmolb.2022.793403. eCollection 2022.
Genomic features, including tumor mutation burden (TMB), microsatellite instability (MSI), and somatic copy number alteration (SCNA), had been demonstrated to be involved with the tumor microenvironment (TME) and outcome of gastric cancer (GC). We obtained profiles of TMB, MSI, and SCNA by processing 405 GC data from The Cancer Genome Atlas (TCGA) and then conducted a comprehensive analysis though "iClusterPlus." A total of two subgroups were generated, with distinguished prognosis, somatic mutation burden, copy number changes, and immune landscape. We revealed that Cluster1 was marked by a better prognosis, accompanied by higher TMB, MSIsensor score, TMEscore, and lower SCNA burden. Based on these clusters, we screened 196 differentially expressed genes (DEGs), which were subsequently projected into univariate Cox survival analysis. We constructed a 9-gene immune risk score (IRS) model using LASSO-penalized logistic regression. Moreover, the prognostic prediction of IRS was verified by receiver operating characteristic (ROC) curve analysis and nomogram plot. Another independent Gene Expression Omnibus (GEO) contained specimens from 109 GC patients was designed as an external validation. Our works suggested that the 9-gene-signature prediction model, which was derived from TMB, MSI, and SCNA, was a promising predictive tool for clinical outcomes in GC patients. This novel methodology may help clinicians uncover the underlying mechanisms and guide future treatment strategies.
基因组特征,包括肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)和体细胞拷贝数改变(SCNA),已被证明与胃癌(GC)的肿瘤微环境(TME)和预后有关。我们通过处理来自癌症基因组图谱(TCGA)的405份GC数据获得了TMB、MSI和SCNA的图谱,然后通过“iClusterPlus”进行了全面分析。总共生成了两个亚组,它们在预后、体细胞突变负荷、拷贝数变化和免疫景观方面存在差异。我们发现Cluster1的预后较好,伴有较高的TMB、MSIsensor评分、TMEscore和较低的SCNA负担。基于这些聚类,我们筛选了196个差异表达基因(DEG),随后将其纳入单变量Cox生存分析。我们使用LASSO惩罚逻辑回归构建了一个9基因免疫风险评分(IRS)模型。此外,通过受试者工作特征(ROC)曲线分析和列线图验证了IRS的预后预测。另一个包含109例GC患者样本的独立基因表达综合数据库(GEO)被设计用于外部验证。我们的研究表明,源自TMB、MSI和SCNA的9基因特征预测模型是GC患者临床结局的一种有前景的预测工具。这种新方法可能有助于临床医生揭示潜在机制并指导未来的治疗策略。